Low-Dose Aspirin Shows No Long-Term Benefits for Healthy Aging in Older Adults

This landmark study addresses a critical question in aging research: whether low-dose aspirin can extend healthy lifespan in older adults. With global initiatives focused on increasing healthy life expectancy, researchers sought to determine if aspirin's known anti-inflammatory and potential anti-aging properties could benefit seniors.

The ASPREE-XT observational study followed 15,633 community-dwelling adults (predominantly 70+ years) for a median of 4.3 years after they completed the original ASPREE randomized trial. Participants had previously taken either 100mg daily aspirin or placebo for 4.7 years. Researchers measured 'healthy lifespan' as survival free from dementia, persistent physical disability, or death.

The results were definitively negative. There was no legacy effect from previous aspirin use (34.4 vs 33.7 events per 1000 person-years for aspirin vs placebo groups). Over nearly a decade of total follow-up, aspirin showed no long-term benefits for healthy lifespan (HR 1.01), death prevention (HR 1.06), or individual components like dementia or disability. Notably, aspirin was associated with a 24% increased risk of major hemorrhagic events over the long term.

These findings are significant because they definitively challenge the hypothesis that aspirin could serve as a simple, accessible intervention for healthy aging. Despite laboratory evidence showing aspirin's anti-senescence properties and ability to reduce cellular aging markers, these benefits did not translate to real-world improvements in healthy lifespan for older adults.

The study's strength lies in its large scale, long duration, and rigorous methodology with blinded expert adjudication of outcomes. However, participants were relatively healthy at baseline, so results may not apply to those with existing health conditions who might benefit from aspirin's cardiovascular protective effects.